Literature DB >> 11821803

A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000.

Takashi Kanematsu1, Junichiro Furui, Katsuhiko Yanaga, Sadayuki Okudaira, Mitsuo Shimada, Ken Shirabe.   

Abstract

BACKGROUND: Hepatic resection is an accepted therapeutic modality for hepatocellular carcinoma (HCC). Over the past 2 decades, liver surgery has evolved to a refined and deliberate operation. In the present study surgical results are analyzed with an aim toward further improving the treatment of HCC.
METHODS: We studied 303 patients with HCC who underwent a hepatic resection at 2 university hospitals from 1985 through 2000. Living-related liver transplantation was a procedure of choice in 1 patient with early staged HCC. Fifty-five percent of the patients had associated cirrhosis. Before the operation, the liver function was mainly evaluated with the indocyanine green retention test.
RESULTS: The mortality rate within 30 days after the operation was 1.6%. One-, 3-, 5-, 10-, and 15-year cumulative survival rates were 84%, 67%, 51%, 20%, and 11%, respectively. The tumor stage I and II groups showed superior survival rates to those of the tumor stage III and IV groups, respectively, and the difference was statistically significant. The disease-free survival curves, however, showed the rate to be 27% at 5 years and 11% at 10 years.
CONCLUSIONS: Although the surgical results have greatly improved in the treatment of HCC, the recurrence rate is still high. In carefully screened patients with poor liver function and small HCC, liver transplantation enhances the possibility of cure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821803     DOI: 10.1067/msy.2002.119497

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma.

Authors:  Hai-Gang Li; De-Rong Xie; Xi-Ming Shen; Hong-Hao Li; Hong Zeng; Yun-Jie Zeng
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion.

Authors:  Skye C Mayo; Andrew D Shore; Hari Nathan; Barish H Edil; Kenzo Hirose; Robert A Anders; Christopher L Wolfgang; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2011-05-18       Impact factor: 3.647

3.  Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma.

Authors:  Terence P F Gade; Elizabeth Tucker; Michael S Nakazawa; Stephen J Hunt; Waihay Wong; Bryan Krock; Charles N Weber; Gregory J Nadolski; Timothy W I Clark; Michael C Soulen; Emma E Furth; Jeffrey D Winkler; Ravi K Amaravadi; M Celeste Simon
Journal:  Radiology       Date:  2017-03-02       Impact factor: 11.105

Review 4.  Management of hepatocellular carcinoma.

Authors:  Janice N Cormier; K Tyson Thomas; Ravi S Chari; C Wright Pinson
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

5.  Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy.

Authors:  Sung Hoon Kim; Sae Byeol Choi; Jae Gil Lee; Seung Up Kim; Mi-Suk Park; Do Young Kim; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2011-02-19       Impact factor: 3.452

6.  Patient selection for surgical management of primary and metastatic liver cancers: current perspectives.

Authors:  J Alexander Palesty; Mazin Al-Kasspooles; John F Gibbs
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

7.  Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98.

Authors:  Chao-Yang Lou; Ying-Ming Feng; Ai-Rong Qian; Yu Li; Hao Tang; Peng Shang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

8.  Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.

Authors:  Yun-Le Wan; Shu-Sen Zheng; Zhi-Cheng Zhao; Min-Wei Li; Chang-Ku Jia; Hao Zhang
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

9.  Liver resection for hepatocellular carcinoma in a hepatitis B endemic area.

Authors:  Adam St J R Bartlett; John L McCall; Jonathan B Koea; Andrew Holden; Mee-Ling Yeong; Nishanthi Gurusinghe; Ed Gane
Journal:  World J Surg       Date:  2007-07-04       Impact factor: 3.352

Review 10.  Operative mortality after hepatic resection: are literature-based rates broadly applicable?

Authors:  Bolanle Asiyanbola; David Chang; Ana Luiza Gleisner; Hari Nathan; Michael A Choti; Richard D Schulick; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-02-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.